Leerink Partners analyst David Risinger has reiterated their bullish stance on REGN stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Risinger has given his Buy rating due to a combination of factors that highlight Regeneron’s promising developments in the anticoagulation market. The company is advancing its Factor XI programs, which are seen as underappreciated by the investment community, with potential to significantly impact the market. Regeneron’s management is optimistic about these programs, referring to them as a potential “mega category,” and anticipates that their novel Factor XI antibodies could offer a more convenient and effective alternative to existing small-molecule drugs.
Regeneron’s strategy involves developing two distinct Factor XI antibodies, REGN7508 and REGN9933, each tailored to address different clinical needs. REGN7508 is noted for its strong coagulation blockade, targeting the catalytic domain of FXI, while REGN9933 is highlighted for its safety profile. The company’s approach could potentially double the current $20 billion annual run rate of the anticoagulant market if successful. This strategic development, along with the anticipated fast-to-market regulatory pathway and additional pivotal trials, supports Risinger’s optimistic outlook on Regeneron’s stock.
In another report released yesterday, Evercore ISI also maintained a Buy rating on the stock with a $750.00 price target.